Irish biopharmaceutical company Poolbeg Pharma has reached an important milestone in the clinical development of POLB 001, with an interim safety review supporting the continued progression of its UK oncology trial.

The company said the interim safety cohort in its TOPICAL trial had been reviewed positively and recommended to continue as planned, with no changes required to the study protocol. Recruitment is continuing across leading UK clinical sites, with further patients expected to be enrolled and additional sites activated. Poolbeg’s regulatory announcement describes the review as a key milestone for the POLB 001 programme.

The trial is evaluating POLB 001 as a preventative therapy for CRS in patients with relapsed or refractory multiple myeloma receiving teclistamab. The programme is focused on addressing a treatment-related complication associated with some advanced cancer immunotherapies.

Headquartered in Dublin and listed on London’s AIM market, Poolbeg is a clinical-stage biopharmaceutical company focused on developing treatments across areas including oncology, infectious diseases and metabolic disorders. The company was co-founded by entrepreneur Cathal Friel and is building its pipeline through international clinical development programmes.

The latest development is particularly relevant to Ireland’s pharmaceutical and biotechnology sector because it shows an Irish-founded company progressing a specialised clinical programme through established UK research infrastructure. The combination of Irish biotech expertise and international clinical networks provides a route for locally based companies to develop therapies for wider patient populations.

The Irish Independent reported that the TOPICAL trial is being conducted at UK sites including The Christie in Manchester, Royal Marsden and University College London Hospitals. These partnerships give Poolbeg access to specialist oncology expertise while generating clinical data needed to advance POLB 001.

The programme also forms part of a wider research collaboration. Poolbeg is the lead business partner in the RISE programme, supported by a £3.4 million UK Medical Research Council Prosperity Partnership grant and led by the University of Manchester and The Christie. The initiative is investigating approaches to improve the safety and effectiveness of immunotherapy treatments.

Poolbeg’s POLB 001 oncology programme remains focused on the potential use of the drug to prevent CRS. While the interim review relates to safety and continuation of the study, further clinical data will be needed to establish whether the treatment provides the intended therapeutic benefit.

For the sector, Poolbeg’s progress highlights the role of Irish biotech companies in developing specialised therapies through international clinical partnerships. Continued clinical validation and collaboration with specialist research centres can help promising programmes move towards wider patient populations and commercial opportunities.

Source: Irish Independent / Poolbeg Pharma / The Christie